Trial Profile
A Phase I, Open-label, Dose Escalation Study of Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2021
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 01 Mar 2021 Planned number of patients changed from 36 to 24.
- 01 Mar 2021 Status changed from active, no longer recruiting to completed.
- 04 Feb 2020 Planned End Date changed from 1 Jul 2018 to 1 Dec 2020.